Cell and Gene Commercialization

  1. What Does InspiroGene Bring To The CGT Space And To The Patients It Serves? 12/30/2024

    Joe DePinto, Head of Cell Gene and Advanced Therapies at McKesson, discusses what InspiroGene brings to the cell and gene therapy (CGT) space and the patients it serves.

  2. Bridging The Gap Between CGT Innovation And Reality 12/30/2024

    Learn about the range of services provided by InspiroGene By McKesson and the company’s unique points of difference as a commercial ally to stakeholders in the CGT industry.

  3. What's Next For Cell And Gene Therapies: Addressing Key Challenges 12/30/2024

    Delve into this exploration of the challenges and opportunities facing CGTs, including manufacturing, supply chain logistics, and the need for greater collaboration among stakeholders.

  4. U.S. Oncologists See Promise In CGTs, But Barriers Loom 12/30/2024

    Explore the findings of a survey of 124 U.S. oncologists focused on better understanding the current use of cell and gene therapies (CGTs) and possible barriers to future adoption.

  5. Optimism For Biopharma In 2025 12/27/2024

    In this closing segment from the executive roundtable discussion, our panelists express their confidence in the industry's mission and maintain a positive outlook for the years ahead.

  6. How Biotechs Can Navigate Market Uncertainty In 2025 12/27/2024

    In this segment of the executive roundtable discussion, our panelists weigh in on how to prepare for what may be a challenging financial climate in 2025. 

  7. Exciting Areas Of Innovation For Cell Therapies 12/23/2024

    In this segment of the executive roundtable discussion, our panelists express optimism about the promising future of allogeneic cell therapies and discuss other innovations in the field.

  8. Executive Roundtable: Cell Therapy Predictions For 2025 And Beyond 12/17/2024

    In this executive roundtable discussion, Bioprocess Online editor Tyler Menichiello is joined by CEO, co-founder, and president of Ossium Health, Kevin Caldwell, CSO of FibroBiologics, Hamid Khoja, Ph.D., and president and acting CEO of Triumvira Immunologics, Rob Williamson. The panelists share their predictions and thoughts on the industry’s direction heading into 2025. They cover manufacturing trends (noting opportunities for improvements in cell therapy manufacturing), AI adoption, regulatory concerns, and the potentially challenging funding environment ahead. 

  9. Expand The Use And Value Of Your Product Over Time 12/2/2024

    This discussion explores a forward-thinking approach that encourages biotech companies to look beyond initial approval, exploring new indications, markets, and patient populations.

  10. Implement Market Launch Strategy, Pre-Approval 12/2/2024

    By focusing on proactive planning and risk mitigation, this episode offers biotech leaders actionable insights to optimize their pre-launch strategies, setting the stage for a strong market debut and sustained commercial success.